Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMTC vs SOLV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SOLV Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

SOLV Overall Winner 6-Pillar Tally: NMTC 0 – 6 SOLV Matrix Metrics: NMTC 2 – 8 SOLV

As of Nov 20, 2026, Solventum Corporation (SOLV) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas SOLV carries 41.4/100 (SELL) at $84.50 (11.2x Forward P/E, 5.9% operating margin).

  • Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SOLV 41.4/100 SELL), SOLV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.9% vs. -63.4% operating margin) and revenue trajectory (-7.0% vs. +16.3% YoY).
  • Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile SOLV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMTC vs SOLV
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03
SOLV NYSE Head-to-Head Winner
Solventum Corporation
Surgical & Medical Instruments & Apparatus
$84.50
-1.52% 1D
Market Cap $14.6B
TTM Revenue $8.16B
Forward P/E 11.2x
Beta / 30D Vol 0.51β · 36% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.5%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $86.52 · SMA50: $87.21

6-Pillar Scorecard Institutional Category Breakdown (NMTC 0 – 6 SOLV)

Columns: Metric · NMTC · SOLV
1. Valuation Multiples SOLV
Forward P/E N/M 11.2x
Trailing P/E N/M 96.4x
PEG Ratio N/M 1.22x
EV / Revenue 0.3x 2.4x
2. Growth & Scale SOLV
Revenue Growth (YoY) +16.3% -7.0%
Earnings Growth (YoY) +0.0% +3.9%
TTM Revenue (USD) $12M $8.16B
Market Cap $6.1M $14.6B
3. Profitability & Quality SOLV
Gross Margin 23.0% 53.8%
Operating Margin -63.4% 5.9%
Net Profit Margin -59.7% 1.9%
Return on Equity (ROE) -124.7% 3.2%
4. Balance Sheet & Cash Flow SOLV
Cash Generation (TTM) -$7.6M $0
Cash Flow Margin -60.7% 0.0%
Net Cash / Leverage $2.6M Net Cash $4.82B Net Debt (1.10x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SOLV
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 54.9% (22nd %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat SOLV
OpEx & R&D Intensity N/A 47.9% of Rev ($3.91B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMTC (2) vs SOLV (8)
Institutional Metric NMTC SOLV Criterion Row Edge
Market Capitalization
Scale
$6.1M $14.6B Larger Scale SOLV
Trailing P/E Ratio
Valuation
N/M 96.4x Lower Multiple SOLV
Forward P/E Ratio
Valuation
N/M 11.2x Lower Multiple SOLV
Revenue Growth (YoY)
Growth
+16.3% -7.0% Higher Growth NMTC
Operating Margin (TTM)
Profitability
-63.4% 5.9% Higher Margin SOLV
Net Profit Margin
Profitability
-59.7% 1.9% Higher Margin SOLV
Return on Equity (ROE)
Capital Efficiency
-124.7% 3.2% Higher ROE SOLV
52-Week Range Position
Momentum
2% ($1–$5) 70% ($62–$94) Stronger Trend SOLV
Beta / 30D Volatility
Risk Regime
1.55β · 105% Vol 0.51β · 36% Vol Lower Realized Risk SOLV
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 41.4 / 100 (SELL) Higher Composite NMTC
Trailing 12M Revenue (USD)
Operating Scale
$12M $8.16B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.0% 53.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 1.22x PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($2.6M Net Cash) $0 ($4.82B Net Debt (1.10x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SOLV +30.09 pp
NMTC: -33.46% · SOLV: -3.37%
3M Horizon SOLV +62.13 pp
NMTC: -69.53% · SOLV: -7.4%
6M Horizon SOLV +92.31 pp
NMTC: -82.33% · SOLV: +9.98%
1Y Horizon SOLV +5.81 pp
NMTC: +3.49% · SOLV: +9.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NMTC Revenue SOLV Revenue NMTC Op. Margin SOLV Op. Margin Margin Leader
FY2012 $0M N/A -1491.1% N/A NMTC
FY2013 $0M N/A -2009.0% N/A NMTC
FY2014 $0M N/A -4646.1% N/A NMTC
FY2021 $0M N/A -5735.9% N/A NMTC
FY2022 $0M $8.13B -5860.2% 20.8% SOLV
FY2023 $0M $8.20B -612.3% 20.6% SOLV
FY2024 $0M $8.25B -344.3% 12.6% SOLV
FY2025 $10M $8.32B -46.5% 26.2% SOLV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SOLV CONSOLIDATION
115d in phase · OBV DISTRIBUTION
Current IV 54.9%
IV Percentile 22nd %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SOLV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $87.06 · IV 34.0%

SOLV Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($8,706)

Compare $8,706 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 34.0% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $85 / $90 Bull Call Spread

Buy 1x $85C · Sell 1x $90C · 30d

Net Entry $184 Debit
T+5d @ +5% Move +$122 (+66%)
Max Risk / Buffer $184 Capped
5d Edge & Liquidity 1.1x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $80 / $75 Bull Put Spread

Sell 1x $80P · Buy 1x $75P · 58d

Net Entry $104 Credit
Max Credit / Yield +$104 (+26.3% RoM)
Max Risk / Buffer -9.3% Cushion ($396 Mgn)
5d Edge & Liquidity 80% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SOLV Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $14.6B market capitalization and 5.9% operating margin.
OpEx & R&D Reinvestment 47.9% of Rev ($3.91B)
90D Engineering Disclosures 0 Published

Investor FAQ NMTC vs SOLV Key Questions & Quantitative Answers

As of Nov 20, 2026, Solventum Corporation (SOLV) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas SOLV carries 41.4/100 (SELL) at $84.50 (11.2x Forward P/E, 5.9% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. SOLV 41.4/100 SELL), SOLV captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.9% vs. -63.4% operating margin) and revenue trajectory (-7.0% vs. +16.3% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile SOLV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SOLV leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with SOLV at -7.0% YoY revenue growth and +3.9% YoY earnings growth on $8.16B TTM revenue (53.8% gross margin, 5.9% operating margin). Across the 8-period historical trajectory (FY2012 to FY2025), NMTC cumulative revenue shifted N/A while SOLV shifted +2.3%. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus 47.9% of Rev ($3.91B) (0 disclosures) for SOLV.

SOLV screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas SOLV trades at 11.2x Forward P/E, 96.4x Trailing P/E, 1.22x PEG, and 2.4x EV/Revenue (0.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus SOLV (3.2% ROE) capital efficiency.

In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, SOLV carries 54.9% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.51β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.